Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU

Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU

Shots:

  • The EC’s MAA is based on the P-III APPROACH study results assessing of Waylivra vs PBO in 66 patients with FCS and the ongoing APPROACH OLE study and is supported by P-III COMPASS study results
  • The P-III APPROACH study resulted in the reduction in triglyceride levels (77% vs 18%) with a reduction in apoC-III by 84% and were published in the August 8th issue of the NEJM entitled “Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.”
  • Waylivra is the only therapy and is based on Ionis’ antisense technology act by reducing the production of apoC-III, thus regulating plasma triglycerides. Akcea is working to confirm a path forward for WAYLIVRA in the US and Canada

Click here to­ read full press release/ article | Ref: Akcea Therapeutics | Image: Pharma Journalist